A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244)
Boers-Sonderen, Marye J., Desar, Ingrid M., Blokx, Willeke, Timmer-Bonte, Johanna N., van Herpen, Carla M.Volume:
23
Language:
english
Journal:
Anti-Cancer Drugs
DOI:
10.1097/cad.0b013e328350737d
Date:
August, 2012
File:
PDF, 306 KB
english, 2012